MCID: MLG008
MIFTS: 15

Malignant Breast Melanoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Malignant Breast Melanoma

MalaCards integrated aliases for Malignant Breast Melanoma:

Name: Malignant Breast Melanoma 12
Malignant Melanoma of Breast 12 69
Breast Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4364
NCIt 47 C8410
SNOMED-CT 64 188050009
UMLS 69 C0346787

Summaries for Malignant Breast Melanoma

MalaCards based summary : Malignant Breast Melanoma, is also known as malignant melanoma of breast. The drugs Edetic Acid and Anticoagulants have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and brain.

Related Diseases for Malignant Breast Melanoma

Symptoms & Phenotypes for Malignant Breast Melanoma

Drugs & Therapeutics for Malignant Breast Melanoma

Drugs for Malignant Breast Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
2 Anticoagulants Phase 4
3 Blood Substitutes Phase 4
4 Chelating Agents Phase 4
5 Dextrans Phase 4
6 Pentetic Acid Phase 4
7 Plasma Substitutes Phase 4
8 Radiopharmaceuticals Phase 4
9 Technetium Tc 99m Pentetate Phase 4
10 Technetium Tc 99m Sulfur Colloid Phase 4
11
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
12
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
13
Bupivacaine Approved, Investigational Phase 3 2180-92-9, 38396-39-3 2474
14
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
15
Morphine Approved, Investigational Phase 3,Phase 2 57-27-2 5288826
16 Racepinephrine Approved Phase 3,Phase 2
17
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
18
Sufentanil Approved, Investigational Phase 3 56030-54-7 41693
19
Propranolol Approved, Investigational Phase 2, Phase 3,Phase 1 525-66-6 4946
20 Vaccines Phase 3,Phase 2,Phase 1
21 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
22 Alkylating Agents Phase 3,Phase 2,Phase 1
23 Antiemetics Phase 3
24 Antimitotic Agents Phase 3,Phase 1,Phase 2
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
26 Adjuvants, Anesthesia Phase 3
27 Analgesics Phase 3
28 Analgesics, Opioid Phase 3
29 Anesthetics Phase 3
30 Anesthetics, General Phase 3
31 Anesthetics, Intravenous Phase 3
32 Anesthetics, Local Phase 3
33 Central Nervous System Depressants Phase 3
34 Epinephryl borate Phase 3,Phase 2
35 Narcotics Phase 3
36 Peripheral Nervous System Agents Phase 3
37 Adrenergic Agents Phase 2, Phase 3,Phase 1
38 Adrenergic Antagonists Phase 2, Phase 3,Phase 1
39 Adrenergic beta-Antagonists Phase 2, Phase 3,Phase 1
40 Anti-Arrhythmia Agents Phase 2, Phase 3,Phase 1
41 Antihypertensive Agents Phase 2, Phase 3,Phase 1
42 Neurotransmitter Agents Phase 2, Phase 3,Phase 1
43 Vasodilator Agents Phase 2, Phase 3,Phase 1
44 Tea Nutraceutical Phase 3
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
47
Trastuzumab Approved, Investigational Phase 1, Phase 2 180288-69-1 9903
48
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 52)

id Name Status NCT ID Phase Drugs
1 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
2 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
3 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
4 A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Completed NCT00864253 Phase 3 ABI-007;Dacarbazine
5 Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy Completed NCT01367418 Phase 3 Patient controlled analgesia (PCA);Thoracic Epidural Analgesia (TEA)
6 Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery Recruiting NCT01318161 Phase 3 Ropivacaine + opioid epidurally;Morphine
7 MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients Not yet recruiting NCT02962947 Phase 2, Phase 3 Propranolol;Placebo
8 Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) Completed NCT00831545 Phase 2 Temozolomide
9 An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed NCT01386580 Phase 1, Phase 2 2B3-101;Trastuzumab;2B3-101 60 mg/m2 every 4 weeks;2B3-101 50 mg/m2 every 3 weeks
10 Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors Completed NCT02038218 Phase 2 4-Demethyl-4-cholestryloxycarbonylpenclomedine
11 An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclita Completed NCT01618136 Phase 1, Phase 2 E7449 alone;E7449 plus TMZ;E7449 plus carboplatin and paclitaxel
12 Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed NCT00976573 Phase 2 carboplatin;everolimus;paclitaxel
13 Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery Completed NCT00281957 Phase 2 sorafenib tosylate;tipifarnib;temsirolimus
14 Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors Completed NCT00855452 Phase 2
15 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
16 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
17 A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy Recruiting NCT02971748 Phase 2 Pembrolizumab
18 Thermal Ablation and Stereotactic Spine Radiosurgery (SSRS) Recruiting NCT02713269 Phase 2
19 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Recruiting NCT02465060 Phase 2 Afatinib;Akt inhibitor AZD5363;Binimetinib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib;WEE1 Inhibitor AZD1775
20 Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors Recruiting NCT02644369 Phase 2
21 Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer Active, not recruiting NCT02129556 Phase 1, Phase 2 MK-3475
22 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Tria Not yet recruiting NCT02732678 Phase 1, Phase 2 PROPRANOLOL
23 Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) Not yet recruiting NCT03040791 Phase 2 Nivolumab
24 Lapatinib in Stage IV Melanoma With ERBB4 Mutations Terminated NCT01264081 Phase 2 Lapatinib
25 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Terminated NCT01120275 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
26 Sentinel Node in Ovarian Cancer Unknown status NCT01734746 Phase 1
27 Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Completed NCT00978913 Phase 1
28 Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma Completed NCT00862901 Phase 1
29 Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors Completed NCT00667641 Phase 1 bortezomib;paclitaxel
30 Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies Completed NCT00703625 Phase 1 Temsirolimus;Docetaxel
31 Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients Completed NCT01337765 Phase 1 BEZ235 + MEK162
32 Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies Completed NCT00703170 Phase 1 Temsirolimus;Pegylated liposomal doxorubicin
33 Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Completed NCT01017185 Phase 1 HF10
34 Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors Completed NCT01639911 Phase 1 Alisertib;Pazopanib
35 A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma Recruiting NCT02922764 Phase 1 RGX-104
36 Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients Active, not recruiting NCT01363232 Phase 1 BKM120 + MEK162
37 Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery Withdrawn NCT00006126 Phase 1 busulfan;cyclophosphamide;etoposide;fludarabine phosphate
38 A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics Completed NCT01775514
39 Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. Completed NCT00974610
40 Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma Completed NCT02316795 Early Phase 1 Indocynanine Green
41 Enhancement of the Prediction of Chemotherapy Prescribing Errors for Oncology Patients Completed NCT02435290
42 Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass Completed NCT01433302
43 Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers Completed NCT00773071
44 Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) Recruiting NCT03060356 Early Phase 1
45 Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma Recruiting NCT02650492
46 Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer Recruiting NCT03039127
47 EPR Tumor Oximetry With CE India Ink Recruiting NCT03321903
48 Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN) Recruiting NCT01104077
49 Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers Recruiting NCT02690428
50 The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells Recruiting NCT01879436

Search NIH Clinical Center for Malignant Breast Melanoma

Genetic Tests for Malignant Breast Melanoma

Anatomical Context for Malignant Breast Melanoma

MalaCards organs/tissues related to Malignant Breast Melanoma:

39
Breast, Lung, Brain, Prostate, Lymph Node, B Cells, T Cells

Publications for Malignant Breast Melanoma

Variations for Malignant Breast Melanoma

Expression for Malignant Breast Melanoma

Search GEO for disease gene expression data for Malignant Breast Melanoma.

Pathways for Malignant Breast Melanoma

GO Terms for Malignant Breast Melanoma

Sources for Malignant Breast Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....